| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/30/2002 | EP1175508A1 Optical probes and assays |
| 01/30/2002 | EP1175504A1 Dna encoding the human vanilloid receptor vr1 |
| 01/30/2002 | EP1175503A1 49 human secreted proteins |
| 01/30/2002 | EP1175490A2 Tyrosine kinase substrate (tks) proteins |
| 01/30/2002 | EP1175443A1 Modified exendins and exendin agonists |
| 01/30/2002 | EP1175412A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 01/30/2002 | EP1175409A1 Pyrimidinones derivatives for the treatment of atherosclerosis |
| 01/30/2002 | EP1175246A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS |
| 01/30/2002 | EP1175224A2 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
| 01/30/2002 | EP1175223A2 Methods and compositions for modulating an immune response |
| 01/30/2002 | EP1175216A2 Antimalarian agents for the treatment of asthma |
| 01/30/2002 | EP1175214A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 01/30/2002 | EP1175205A2 Inhibitors of crystallization in a solid dispersion |
| 01/30/2002 | EP1045897B1 Enzyme catalyzed therapeutic agents |
| 01/30/2002 | EP1001765A4 Internal two photon excitation device for delivery of pdt to diffuse abnormal cells |
| 01/30/2002 | EP0904539A4 Inhibiting protein interactions |
| 01/30/2002 | EP0896521A4 Composition, barrier film, and method for preventing contact dermatitis |
| 01/30/2002 | EP0832198A4 Oxygen activatable formulations for disinfection or sterilization |
| 01/30/2002 | EP0777480A4 Optic nerve health |
| 01/30/2002 | EP0668913B1 Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
| 01/30/2002 | CN1333873A HIV-specfic T-cell induction |
| 01/30/2002 | CN1333832A Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/30/2002 | CN1333698A Combination chemotherapy |
| 01/30/2002 | CN1333691A Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| 01/30/2002 | CN1333684A Use of 5HT3 receptor antagouists for the treatment of chronic fatigue syndrome |
| 01/30/2002 | CN1333683A Pharmaceutical composition for modified release insulin sensitiser |
| 01/30/2002 | CN1333682A Storable active substance concentrate with formoterol |
| 01/30/2002 | CN1333681A Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood tribly cerides |
| 01/29/2002 | US6342584 Antiproliferative, anticarcinogenic, antitumor, antiinflammatory, and antimetastasis agents; diabetes, restenosis, rheumatoid arthritis treatment; genetic engineering |
| 01/29/2002 | US6342528 Control of microbial populations in the gastrointestinal tract of animals |
| 01/29/2002 | US6342510 Antiinflammatory agents and enzyme inhibitors |
| 01/29/2002 | US6342496 Bupropion metabolites and methods of use |
| 01/29/2002 | US6342487 Compositions containing at least one farnesyl transferase inhibitor and at least one topoisomerase inhibitor and compositions containing at least one farnesyl transferase inhibitor and at least one taxoid |
| 01/29/2002 | US6342485 Antitumor agents with nucleic acids |
| 01/29/2002 | US6342480 Tumor-activated prodrug compounds and treatment |
| 01/29/2002 | US6342376 Two-color differential display as a method for detecting regulated genes |
| 01/29/2002 | US6342351 Methods and compositions for diagnosing and treating chromosome-18p related disorders |
| 01/29/2002 | US6342251 Compositions for nasal administration |
| 01/29/2002 | US6342246 Image forms and method for ameliorating male erectile dysfunction |
| 01/29/2002 | US6342221 Antibody conjugate compositions for selectively inhibiting VEGF |
| 01/29/2002 | US6342219 As anti-angiogenic and in tumor therapy |
| 01/29/2002 | US6342216 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
| 01/29/2002 | CA2237780C Reduction of hair growth |
| 01/29/2002 | CA2207624C Selective and non-invasive visualization or treatment of vasculature |
| 01/29/2002 | CA2031368C Composition comprising non-steroidal non-inflammatory agent and effectively non-antibacterial tetracycline |
| 01/28/2002 | CA2354208A1 Compositions and methods for treating cataracts |
| 01/28/2002 | CA2354110A1 Use of agonists of the prostaglandin ep 3 receptor as a cosmetic agent to mitigate, reduce or stop hair growth |
| 01/28/2002 | CA2354109A1 Use of non-prostanoid agonists of prostaglandin e2 and/or ep-4 receptors as a cosmetic agent for mitigating, reducing or stopping hair loss |
| 01/28/2002 | CA2354108A1 Use of agonists of the prostaglandin ep 3 receptor to mitigate, reduce or stop hair growth in cosmetic preparations |
| 01/28/2002 | CA2354107A1 Topical compounds including glucosyl hydroxystilbenes and uses |
| 01/27/2002 | CA2353768A1 Use of growth hormone secretagogues for improvement of functional health status |
| 01/24/2002 | WO2002006821A2 Antimicrobial agent |
| 01/24/2002 | WO2002006515A2 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 01/24/2002 | WO2002006492A1 A novel human soluble secreted endopeptidase (sep) for the treatment of sexual dysunfction |
| 01/24/2002 | WO2002006482A1 Receptor protein specifically recognizing bacterial dna |
| 01/24/2002 | WO2002006460A2 Masp-2, a complement-fixing enzyme, and uses for it |
| 01/24/2002 | WO2002006453A2 Regulation of human desc1-like serine protease |
| 01/24/2002 | WO2002006349A1 Gel compositions containing metronidazole |
| 01/24/2002 | WO2002006317A2 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 01/24/2002 | WO2002006316A2 Alpha-msh related compounds and methods of use |
| 01/24/2002 | WO2002006306A2 SUBSTRATES AND ASSAYS FOR β-SECRETASE ACTIVITY |
| 01/24/2002 | WO2002006282A1 Molecules capable of binding to telomere and the like and method with the use of the same |
| 01/24/2002 | WO2002006253A1 Valsartan salts |
| 01/24/2002 | WO2002006213A2 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| 01/24/2002 | WO2002005857A2 Phosphatonin-related gene and methods of use thereof |
| 01/24/2002 | WO2002005853A2 Compositions containing alpha-2-adrenergic agonist components |
| 01/24/2002 | WO2002005852A1 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
| 01/24/2002 | WO2002005851A2 Enhancement of the action of central and peripheral nervous system agents |
| 01/24/2002 | WO2002005850A2 Enhancement of the action of anti-infective agents |
| 01/24/2002 | WO2002005849A2 Transportation of nucleic acid substances |
| 01/24/2002 | WO2002005848A2 Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
| 01/24/2002 | WO2002005843A2 Human rrp sequences and methods of use |
| 01/24/2002 | WO2002005842A2 Preventing airway mucus production by administration of egf-r antagonists |
| 01/24/2002 | WO2002005841A1 Treatment of glycogen storage disease type ii |
| 01/24/2002 | WO2002005836A2 Stimulation of bone growth with thrombin peptide derivatives |
| 01/24/2002 | WO2002005834A2 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions |
| 01/24/2002 | WO2002005829A2 Methods and formultations with probiotic microorganisms and medicaments |
| 01/24/2002 | WO2002005815A1 Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug |
| 01/24/2002 | WO2002005814A1 Use of il-8 receptor antagonists in the treatment of virus infections |
| 01/24/2002 | WO2002005802A1 Method of fundamentally treating common cold |
| 01/24/2002 | WO2002005799A2 Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
| 01/24/2002 | WO2002005797A2 Use of dopamine d2/d3 receptor agonists to treat fibromyalgia |
| 01/24/2002 | WO2002005796A2 Use of a spla2 inhibitor for the treatment of sepsis |
| 01/24/2002 | WO2002005795A2 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 01/24/2002 | WO2002005792A2 Use of matrix metalloprotease inhibitors for the treatment of cancer |
| 01/24/2002 | WO2002005791A2 Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor |
| 01/24/2002 | WO2002005786A1 Pharmaceutical composition improved in peroral absorbability |
| 01/24/2002 | WO2002005782A2 Stable salts of o-acetylsalicyclic with basic amino acids |
| 01/24/2002 | WO2002005774A1 Use of extracted soluble protein fractions |
| 01/24/2002 | WO2002005773A1 Topical treatment of skin |
| 01/24/2002 | WO2001082872A3 A medicinal aerosol formulation |
| 01/24/2002 | WO2001082861A3 Treatment of skin damage using conjugated linoleic acid and ascorbyl fatty acid esters |
| 01/24/2002 | WO2001082780A3 Method for treating cancer, visualizing cell structures, and isolating organelles using organelle crystallizing agents |
| 01/24/2002 | WO2001058869A3 Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| 01/24/2002 | WO2001053324A3 Novel haptotactic peptides |
| 01/24/2002 | WO2001052892A3 Jak/stat pathway inhibitors and the uses thereof |
| 01/24/2002 | WO2001046258A3 Transporters and ion channels |
| 01/24/2002 | WO2001039744A3 Radiation sensitive liposomes |
| 01/24/2002 | WO2001036977A8 Identification of disease markers involving mass-based-separation |
| 01/24/2002 | WO2001036470A3 Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides |